# Ellen Reilly

> Ellen Reilly is the Chief Executive Officer and a board member of Sware, a Boston-based software company building Res_Q, an AI-powered GxP validation platform for the life sciences industry. With roughly four decades in life sciences quality and IT, Reilly has worked at Roche, advised clients at PwC, and led the launch of DocuSign's Part 11 product before taking the helm at Sware in 2023. She frames her work as tackling 'validation debt' - the accumulated, unpaid cost of testing and compliance that slows how quickly pharmaceutical and biotech companies can adopt new software.

- **Role:** Chief Executive Officer at Sware
- **Organizations:** Sware, DocuSign, PwC, Roche
- **Nationality:** American
- **Known for:** Leads Sware as CEO and board member, guiding its Res_Q GxP validation platform., Led the creation and launch of DocuSign's Part 11 product for life sciences compliance., Oversaw Sware's $6M Series B raise in June 2024 (roughly $26M total raised).

## Career timeline

- **Early career** — Began in Quality IT, doing automation implementation and computer system validation in life sciences.
- **Career** — Held roles at large life sciences and pharmaceutical companies, including Roche.
- **Career** — Worked in a life sciences and technology advisory capacity at PwC.
- **Prior to Sware** — Led the creation and launch of DocuSign's Part 11 product for life sciences compliance.
- **2023** — Named Chief Executive Officer of Sware.
- **2024** — Sware closed a $6M Series B round in June, bringing total funding to roughly $26M.
- **2025** — Sware launched an enhanced, AI-powered version of its Res_Q validation platform.

## Achievements

- Leads Sware as CEO and board member, guiding its Res_Q GxP validation platform.
- Led the creation and launch of DocuSign's Part 11 product for life sciences compliance.
- Oversaw Sware's $6M Series B raise in June 2024 (roughly $26M total raised).
- Drove the 2025 launch of an AI-powered Res_Q platform.
- Customer case studies document up to 75% acceleration in validation and 40% time reduction.

## Latest updates

- **2025-10** — Sware launched an enhanced, AI-powered Res_Q platform to advance GxP validation in life sciences.
- **2024-06** — Sware raised a $6M Series B led by First Analysis, bringing total funding to roughly $26M.
- **2023-09** — Sware introduced Ellen Reilly as its new CEO.

## Links

- Website: https://sware.com
- LinkedIn: http://www.linkedin.com/in/ellen-reilly

---

Profile page: https://yespress.io/ellen-reilly
Published by YesPress — https://yespress.io
Last updated: 2026-07-17